Market capitalization | $36.16m |
Enterprise Value | $-20.76m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | -0.42 |
P/S ratio (TTM) P/S ratio | 0.72 |
P/B ratio (TTM) P/B ratio | 0.50 |
Revenue growth (TTM) Revenue growth | 143.30% |
Revenue (TTM) Revenue | $50.00m |
EBIT (operating result TTM) EBIT | $-45.75m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
4 Analysts have issued a Hookipa Pharma, Inc. forecast:
4 Analysts have issued a Hookipa Pharma, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 50 50 |
143%
143%
|
|
Gross Profit | 47 47 |
169%
169%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -46 -46 |
43%
43%
|
Net Profit | -43 -43 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
Head office | United States |
CEO | Malte Peters |
Employees | 151 |
Founded | 2011 |
Website | www.hookipapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.